ESMO TAT 2023 | Optimizing T-cell function in solid tumors using CRISPR and emerging tools

Eliana Ruggiero, PhD, San Raffaele Scientific Institute, Milan, Italy, comments on CRISPR and other newly emerging tools which will assist in discovering how to optimize conditions in the immunosuppressive environment of solid tumors to enable T-cell products to function optimally. While CRISPR offers the unique possibility of disrupting genes and molecules counteracting T-cell efficacy, other emerging technologies further this cause while simultaneously overcoming CRISPR limitations. Base editing methods can create single base-pair mutations, reducing the chance of translocation or off-target gene editing. Prime editing enables the writing of genetic information directly into the desired position within the genome, and epigenome editing enables the manipulation of endogenous gene expression, both moving beyond CRISPR shortcomings in the process. This interview took place at the ESMO Targeted Anticancer Therapies (TAT) Congress 2023 in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.